# Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

> **NCT03827876** · PHASE4 · RECRUITING · sponsor: **Psoriasis Treatment Center of Central New Jersey** · enrollment: 30 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Enstilar 0.005%-0.064% Topical Foam

## Key facts

- **NCT ID:** NCT03827876
- **Lead sponsor:** Psoriasis Treatment Center of Central New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-16
- **Primary completion:** 2019-09-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827876, "Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT03827876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*